FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124010149> ?p ?o ?g. }

• W2124010149 endingPage "e46738" @default.
• W2124010149 startingPage "e46738" @default.
• W2124010149 abstract "The development of targeted molecular therapies has provided remarkable advances into the treatment of human cancers. However, in most tumors the selective pressure triggered by anticancer agents encourages cancer cells to acquire resistance mechanisms. The generation of new rationally designed targeting agents acting on the oncogenic path(s) at multiple levels is a promising approach for molecular therapies. 2-phenylimidazo[2,1-b]benzothiazole derivatives have been highlighted for their properties of targeting oncogenic Met receptor tyrosine kinase (RTK) signaling. In this study, we evaluated the mechanism of action of one of the most active imidazo[2,1-b]benzothiazol-2-ylphenyl moiety-based agents, Triflorcas, on a panel of cancer cells with distinct features. We show that Triflorcas impairs in vitro and in vivo tumorigenesis of cancer cells carrying Met mutations. Moreover, Triflorcas hampers survival and anchorage-independent growth of cancer cells characterized by RTK swapping by interfering with PDGFRβ phosphorylation. A restrained effect of Triflorcas on metabolic genes correlates with the absence of major side effects in vivo. Mechanistically, in addition to targeting Met, Triflorcas alters phosphorylation levels of the PI3K-Akt pathway, mediating oncogenic dependency to Met, in addition to Retinoblastoma and nucleophosmin/B23, resulting in altered cell cycle progression and mitotic failure. Our findings show how the unusual binding plasticity of the Met active site towards structurally different inhibitors can be exploited to generate drugs able to target Met oncogenic dependency at distinct levels. Moreover, the disease-oriented NCI Anticancer Drug Screen revealed that Triflorcas elicits a unique profile of growth inhibitory-responses on cancer cell lines, indicating a novel mechanism of drug action. The anti-tumor activity elicited by 2-phenylimidazo[2,1-b]benzothiazole derivatives through combined inhibition of distinct effectors in cancer cells reveal them to be promising anticancer agents for further investigation." @default.
• W2124010149 created "2016-06-24" @default.
• W2124010149 creator A5008162892 @default.
• W2124010149 creator A5018879936 @default.
• W2124010149 creator A5024211329 @default.
• W2124010149 creator A5032238919 @default.
• W2124010149 creator A5039061487 @default.
• W2124010149 creator A5042629395 @default.
• W2124010149 creator A5050249121 @default.
• W2124010149 creator A5050756163 @default.
• W2124010149 creator A5051114446 @default.
• W2124010149 creator A5066927007 @default.
• W2124010149 creator A5070524152 @default.
• W2124010149 creator A5073976312 @default.
• W2124010149 creator A5086446165 @default.
• W2124010149 creator A5090239201 @default.
• W2124010149 date "2012-10-05" @default.
• W2124010149 modified "2023-09-24" @default.
• W2124010149 title "Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures" @default.
• W2124010149 cites W1527342827 @default.
• W2124010149 cites W1592550864 @default.
• W2124010149 cites W1607745684 @default.
• W2124010149 cites W1966803171 @default.
• W2124010149 cites W1969732147 @default.
• W2124010149 cites W1975833488 @default.
• W2124010149 cites W1980843814 @default.
• W2124010149 cites W1984375602 @default.
• W2124010149 cites W1985328527 @default.
• W2124010149 cites W1990244564 @default.
• W2124010149 cites W1994391878 @default.
• W2124010149 cites W1995658566 @default.
• W2124010149 cites W1996389988 @default.
• W2124010149 cites W1998971866 @default.
• W2124010149 cites W2014275502 @default.
• W2124010149 cites W2014582878 @default.
• W2124010149 cites W2016579969 @default.
• W2124010149 cites W2018547695 @default.
• W2124010149 cites W2020995084 @default.
• W2124010149 cites W2025183726 @default.
• W2124010149 cites W2027684043 @default.
• W2124010149 cites W2028415754 @default.
• W2124010149 cites W2028823456 @default.
• W2124010149 cites W2031588228 @default.
• W2124010149 cites W2032054503 @default.
• W2124010149 cites W2033640874 @default.
• W2124010149 cites W2040566930 @default.
• W2124010149 cites W2058451329 @default.
• W2124010149 cites W2061345986 @default.
• W2124010149 cites W2069421644 @default.
• W2124010149 cites W2084472730 @default.
• W2124010149 cites W2086454484 @default.
• W2124010149 cites W2087312216 @default.
• W2124010149 cites W2087861588 @default.
• W2124010149 cites W2089293776 @default.
• W2124010149 cites W2093371959 @default.
• W2124010149 cites W2098093541 @default.
• W2124010149 cites W2106711839 @default.
• W2124010149 cites W2107061457 @default.
• W2124010149 cites W2109745752 @default.
• W2124010149 cites W2119748423 @default.
• W2124010149 cites W2124138281 @default.
• W2124010149 cites W2126542948 @default.
• W2124010149 cites W2138896702 @default.
• W2124010149 cites W2147794687 @default.
• W2124010149 cites W2155167580 @default.
• W2124010149 cites W2157185143 @default.
• W2124010149 cites W2157485801 @default.
• W2124010149 cites W2158305336 @default.
• W2124010149 cites W2167637849 @default.
• W2124010149 cites W2265556111 @default.
• W2124010149 cites W2283819867 @default.
• W2124010149 cites W2596898062 @default.
• W2124010149 doi "https://doi.org/10.1371/journal.pone.0046738" @default.
• W2124010149 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3465283" @default.
• W2124010149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23071625" @default.
• W2124010149 hasPublicationYear "2012" @default.
• W2124010149 type Work @default.
• W2124010149 sameAs 2124010149 @default.
• W2124010149 citedByCount "9" @default.
• W2124010149 countsByYear W21240101492015 @default.
• W2124010149 countsByYear W21240101492016 @default.
• W2124010149 countsByYear W21240101492017 @default.
• W2124010149 countsByYear W21240101492018 @default.
• W2124010149 countsByYear W21240101492019 @default.
• W2124010149 countsByYear W21240101492020 @default.
• W2124010149 crossrefType "journal-article" @default.
• W2124010149 hasAuthorship W2124010149A5008162892 @default.
• W2124010149 hasAuthorship W2124010149A5018879936 @default.
• W2124010149 hasAuthorship W2124010149A5024211329 @default.
• W2124010149 hasAuthorship W2124010149A5032238919 @default.
• W2124010149 hasAuthorship W2124010149A5039061487 @default.
• W2124010149 hasAuthorship W2124010149A5042629395 @default.
• W2124010149 hasAuthorship W2124010149A5050249121 @default.
• W2124010149 hasAuthorship W2124010149A5050756163 @default.
• W2124010149 hasAuthorship W2124010149A5051114446 @default.
• W2124010149 hasAuthorship W2124010149A5066927007 @default.
• W2124010149 hasAuthorship W2124010149A5070524152 @default.
• W2124010149 hasAuthorship W2124010149A5073976312 @default.

• next